Previous studies have pointed to the ability of plumbagin to inhibit the DNA binding activity of NF-κB [37],[38], thus an IKKα-independent mechanism of NF-κB inhibition by plumbagin in HER2-positive breast cancer cells cannot be ruled out. Here, ERBB2 is linked to breast carcinoma.